Algert Global LLC Voyager Therapeutics, Inc. Transaction History

Algert Global LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$4.82 - $10.09 $138,093 - $289,078	-28,650 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.75 - $9.44 $7,810 - $26,809	-2,840 Reduced 9.02%	28,650 $218,000
Q4 2021 Feb 14, 2022	BUY	$2.47 - $5.55 $39,939 - $89,743	16,170 Added 105.55%	31,490 $85,000
Q3 2021 Nov 15, 2021	BUY	$2.63 - $4.12 $40,291 - $63,118	15,320 New	15,320 $40,000
Q4 2020 Feb 12, 2021	SELL	$7.15 - $12.28 $207,028 - $355,567	-28,955 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$8.05 - $14.21 $478,250 - $844,216	-59,410 Reduced 67.23%	28,955 $365,000
Q1 2020 May 13, 2020	BUY	$6.8 - $14.66 $4,148 - $8,942	610 Added 0.7%	88,365 $809,000
Q4 2019 Feb 18, 2020	BUY	$12.82 - $16.85 $635,102 - $834,749	49,540 Added 129.63%	87,755 $1.22 Million
Q3 2019 Nov 14, 2019	BUY	$16.31 - $28.29 $197,514 - $342,591	12,110 Added 46.39%	38,215 $658,000
Q2 2019 Aug 14, 2019	BUY	$19.18 - $27.88 $186,333 - $270,854	9,715 Added 59.27%	26,105 $711,000
Q1 2019 May 01, 2019	BUY	$8.0 - $19.66 $131,120 - $322,227	16,390 New	16,390 $314,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.